BTK inhibitors have seen success in treating various hematological malignancies, and their approval has been extended to mantle cell lymphoma (MCL). Here, Simon Rule, MD, from Plymouth University, Plymouth, UK, discusses the challenges of treatment resistance, pointing out that the earlier use of BTK inhibitors, such as ibrutinib, lead to more effective treatment together with reduced side effects. Speaking at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Prof. Rule alludes to the potential of the BCL-2 inhibitor venetoclax, and the exciting promise of CAR T-cell therapy in patients previously treated with ibrutinib. Prof. Rule concludes that CAR T-cell therapy will be a key therapeutic option that will be explored over the next few years for treatment of MCL.
Novel treatments for mantle cell lymphoma
